Lilly’s Little Pill: A Sweet Treat for Investors?

They’ve concocted a brew called tirzepatide – a terribly long word, isn’t it? – sold as Mounjaro for those with a sugar-balancing problem, and then as Zepbound for those who’ve decided they’ve had quite enough of themselves. It’s a potion that seems to shrink people, and people, it turns out, are rather keen on shrinking. Demand has been positively frantic, even outstripping the factory’s ability to bubble it up quickly enough. Novo Nordisk, a rival potion-maker, has a similar brew, but we won’t dwell on them. They’re rather dull, really.








